Bern, 13.05.2022 - Swissmedic has authorised an extension of the indication of the Spikevax® COVID-19 vaccine from Moderna to children aged 6 to 11 years, writes the Swiss Federal Council.
Children aged 6 years and over, as opposed to adults and adolescents aged 12 years and above, will receive two half doses (50 micrograms), administered at an interval of four weeks. The main study in children aged 6 to 11 years found that the immune response triggered by the vaccine against the SARS-CoV-2 virus is comparable with that in young adults.
Fever occurred more frequently in children, whereas muscle and joint pains were seen less often than in adolescents or adults. The undesirable effects were generally mild to moderate and lasted for a few days.Vaccination is particularly beneficial for children with previous illnesses in whom the risk of severe COVID-19 is increased.
Children aged 6 to 11 years will receive a half dose of the vaccine (50 rather than 100 micrograms) compared to older children and adults at an interval of four weeks..
Suche nach Stichworten: